Effect of Finerenone in Patients With Non-diabetic Glomerulonephritis

Last updated: March 23, 2025
Sponsor: Alexandria University
Overall Status: Active - Recruiting

Phase

2

Condition

Glomerulonephritis

Treatment

Placebo

Finerenone

Clinical Study ID

NCT06835322
Finerenone and GN
  • Ages > 18
  • All Genders

Study Summary

This study aims to assess the effect of finerenone on proteinuria and GFR progression in patients with non-diabetic glomerulonephritis.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. GN patients on maximum tolerated doses of an ACEi or ARBs together with theirimmunosuppression protocol (if needed) for at least 4 weeks.

  2. urinary protein excretion >500 mg/g.

  3. Adult patients with age above 18 years.

  4. eGFR ≥ 25 mL/ min/1.73 m2.

  5. baseline serum potassium level <5 mEq/L.

Exclusion

Exclusion Criteria:

  1. Patients with diabetes mellitus (type 1 or 2).

  2. Other non-glomerular kidney diseases.

  3. Heart failure.

  4. Breast feeding or pregnancy.

  5. Patients who received medications to treat hyperkalemia 4 weeks before study.

  6. Uncontrolled hypertension (BP > 160/100).

Study Design

Total Participants: 100
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 2
Study Start date:
February 20, 2025
Estimated Completion Date:
September 10, 2025

Study Description

In patients with type 2 diabetes and advanced CKD, finerenone resulted in lower risks of CKD progression and cardiovascular events. Mineralocorticoid receptor over activation in the kidney leads to inflammation and fibrosis with subsequent progressive kidney disease. Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, had more potent anti-inflammatory and ant fibrotic effects than steroidal mineralocorticoid receptor antagonists. Finerenone has been shown to reduce the urinary albumin-to-creatinine ratio in patients with CKD treated with an RAS blocker, while having smaller effects on serum potassium levels than spironolactone.

Glomerulonephritis (GN) is an inflammation affecting kidney glomeruli, and is considered an important cause of CKD. Reducing proteinuria is one of the main therapeutic targets in patients with GN.

Connect with a study center

  • Faculty of Medicine, Aexandria University

    Alexandria, 21526
    Egypt

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.